Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems (NYSE: VEEV) announced its acquisition of Learnaboutgmp, a premier provider of accredited GxP training for life sciences, on August 3, 2021. This acquisition combines Learnaboutgmp's extensive eLearning library, featuring over 170 course titles and 450 microlearning assets, with Veeva's Vault Training, enhancing training efficiency and compliance for clients. Learnaboutgmp will continue its operations independently under its founder, maintaining its presence in both Ireland and the United States, while aiming to address growing compliance needs in the industry.

Veeva Systems announced the addition of 11 new therapeutic areas to its customer intelligence platform, Veeva Link, now covering 12 areas including oncology. The platform provides curated expert profiles and real-time insights to enhance engagement between life sciences teams and global experts. Key areas expanded include cardiology, neurology, and respiratory diseases. Veeva aims to set the industry standard in real-time customer intelligence, supporting better research and patient care. A summit on June 10, 2021, will showcase how Veeva Link aids pharma companies in personalizing customer interactions.

Veeva Systems (NYSE: VEEV) announced the upcoming 2021 Veeva Commercial & Medical North America Summit Connect on June 10, 2021, featuring keynotes from industry leaders at Boehringer Ingelheim, GSK, and UCB. The event will explore digital-first engagement and data innovation approaches. Dr. Cecil T. Holbert and Amanda Romano will open with a discussion on evolving healthcare provider access. There will be over 100 sessions focused on transforming commercial strategies in the life sciences sector.

Veeva Systems reported strong fiscal 2022 Q1 results, achieving total revenues of $433.6 million, a 29% increase year-over-year. Subscription services revenues grew by 26% to $341.1 million. Operating income rose 47% to $128.4 million, with net income increasing 33% to $115.6 million. Non-GAAP metrics showed similar growth, with non-GAAP net income per share reaching $0.91. The company added a record 59 new customers, bringing the total to over 1,000. Veeva's outlook for Q2 anticipates revenues of $450-$452 million, with non-GAAP net income per share projected at $0.85-$0.86.

The Shareholder Commons is advocating for shareholder proposals to compel companies to become Public Benefit Corporations (PBCs), which integrate social and environmental goals with profit. Support for this initiative is growing, backed by governance advisors like PIRC Limited. Significant votes are pending at large firms such as Chevron, BlackRock, and Alphabet. Proponents argue that a legally binding commitment to balance stakeholder interests can protect investor value. Veeva Systems is highlighted as the largest publicly traded PBC, reflecting a shift in corporate purpose.

Veeva Systems (NYSE: VEEV) announced that over 100 organizations have implemented Veeva Vault Training to enhance role-based qualification and comply with industry standards. This integration with Veeva Vault QualityDocs facilitates streamlined document and training management. Customers benefit from features such as seamless learning management, sophisticated curriculum builds, and robust reporting. Veeva aims to address evolving training needs in life sciences, fostering efficiency and compliance across the industry.

On May 19, 2021, Veeva Systems (NYSE: VEEV) announced an increasing adoption of its Veeva Development Cloud by over 650 life sciences companies. This platform integrates applications for clinical, regulatory, quality, and safety functions, designed to eliminate organizational silos and enhance collaboration. Notably, more than 350 companies are using Vault Clinical applications, while more than 250 are optimizing regulatory processes with Vault RIM. The company emphasizes accelerating drug development and improving operational efficiency through its unified applications.

Veeva Systems announced a strategic partnership with Oncopeptides to support the launch of PEPAXTO® (melphalan flufenamide), an FDA-approved anticancer drug for multiple myeloma. Utilizing Veeva Link, Oncopeptides aims to accelerate patient engagement and enhance its commercial strategy. Veeva Link provides real-time insights and expert profiles, facilitating enhanced interactions with healthcare providers. This collaboration signifies Veeva's pivotal role in the life sciences sector, helping to optimize the market launch process for new therapies.

Veeva Systems, the leader in cloud software for life sciences, reports a surge in adoption of its Veeva Vault CTMS, with over 100 companies enhancing their clinical trial management. Companies, including CSL Behring and Atlantic Research Group, have noted significant reductions in operational costs and time, streamlining processes like site monitoring. Veeva Vault CTMS integrates seamlessly with other Veeva products, promoting collaboration and efficiency across clinical studies. The firm continues to focus on improving trial oversight and execution speed.